

# Original Research Article

## Mesothelioma and Small cell lung cancer; bioactive effects of Nigella Sativa in cell lines

### ABSTRACT

**Background:** Lung cancer and malignant mesothelioma are types of cancer with a poor prognosis and fatal. Small cell lung cancer is much more aggressive and survival shorter than non-small cell lung carcinoma. Mesothelioma is a rare malignant disease that commonly affects the pleura. Cisplatin is frequently used in chemotherapy protocols. Thymoquinone is a chemical with antineoplastic effects procured from the Nigella Sativa plant.

**Aims:** It was aimed to investigate the effects of thymoquinone and cisplatin on small cell lung cancer and mesothelioma cell lines.

**Methodology:** The study was done in the Cell Culture Laboratory of Gaziantep University. Cell lines of small cell lung cancer, malignant pleural mesothelioma and non-cancerous bronchial epithelium were used in the study. Cells were cultured in dimethyl sulfoxide. The effective doses of thymoquinone and cisplatin were calculated. Accordingly, which were detected doses of thymoquinone as 100  $\mu\text{M}$  and cisplatin as 200  $\mu\text{M}$ . The viability of cells were evaluated using 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide test. Experiments were repeated 4 times at different times by the same team in the same laboratory. Statistical analysis of the study was done using the Chi-square test. The study was in accordance with international standards on cell lines in the laboratory.

**Results:** Chemical treatments were administered on all cell lines at doses of 100  $\mu\text{M}$  and 200  $\mu\text{M}$ . Thymoquinone at a dose of 100  $\mu\text{M}$ ; viability of cells was detected in 48% in mesothelioma, 44% in small cell lung cancer and 55% in noncancerous epithelium cell lines. Cisplatin at a dose of 200  $\mu\text{M}$ ; viability of cells was detected in 63% in mesothelioma, 48% in small cell lung cancer and 59% in noncancerous epithelium cell lines. There was no significant toxicity of dimethyl sulfoxide used as a chemical solvent when compared with physiological saline.

**Conclusions:** Thymoquinone at a dose of 100  $\mu\text{M}$  was more effective than cisplatin at a dose of 200  $\mu\text{M}$  on both small cell lung cancer and malignant pleural mesothelioma cell lines. Cisplatin was more effective in small cell lung cancer than malignant pleural mesothelioma at a dose of 200  $\mu\text{M}$ . The effects of thymoquinone were similar in both cancer cell lines.

**Key words:** cell lines, cisplatin, lung cancer, mesothelioma, thymoquinone


### INTRODUCTION

Lung cancer and malignant mesothelioma are types of cancer with a poor prognosis and fatal. Lung cancers are categorized as small cell (SCLC) and non-small cell lung carcinoma (NSCLC). SCLC is 14% of all lung cancers. SCLC is much more aggressive and survival shorter than NSCLC. 60% of SCLC is a stage 4 metastatic tumor at the time of diagnosis [1,2]. Unfortunately, surgical treatment cannot be done in lung cancers with the distant metastasis. Chemotherapy is used in lung cancers at this stage. Cisplatin is among the combinations in these chemotherapy protocols [3]. Mesothelioma, which occurs due to asbestos exposure, is a rare malignant disease that commonly affects the pleura [4,5]. Thymoquinone is a bioactive chemical procured from the Nigella Sativa plant. It is shown to have antitumoral and antineoplastic effects [6]. Therefore, it was aimed to investigate the effects of thymoquinone and cisplatin on SCLC and mesothelioma cell lines.

### MATERIALS AND METHOD

The study was done in the Cell Culture Laboratory of Gaziantep University. American Type Culture Collection (ATCC) cell lines were maintained in accordance with international standards in the laboratory. Cell lines of small cell lung cancer (CRL-5853 ATCC-NCI-H1048), malignant pleural mesothelioma (CRL-5820 ATCC-NCI-H28), non-cancerous bronchial epithelium (BEAS-2B ATCC) and non-cancerous pleural epithelium were used in the study (Figure 1A). Cell lines were cultured in dimethyl sulfoxide solution (DMEM) with 10% fetal bovine serum (FBS; Gibco, USA) and 1% antibiotic (Gibco, USA), at 37°C and 5% CO<sub>2</sub> in medium of Roswell Park Memorial Institute (RPMI). The effective doses (ED<sub>50</sub>) of thymoquinone and cisplatin were calculated by administering different doses on the cultured cell lines. Accordingly, the ED<sub>50</sub> of thymoquinone as 100 µM and the ED<sub>50</sub> of cisplatin were determined as 200 µM. Cells were cultured in 10% FBS (RPMI-appropriate medium) for 24 h in 96-well plates (containing 2500/ml cells). The medium was replaced with serum-free medium (for 16 hours) prior to chemical exposure. Cells were treated separately with 100 µM thymoquinone and 200 µM cisplatin for 4 hours under incubation conditions (Figure 1B). DMEM, the solvent of chemical substances, was used as negative control group. The cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide test (MTT) in accordance with international standards. These procedures were done on all cell lines. Experiments were repeated 4 times at different times by the same team in the same laboratory. Statistical analysis of the study was done using the Chi-square test. The study was in accordance with international standards on cell lines in the laboratory.

**Figure 1. Images of cell lines and chemically treated cells**  
A. Image of cell lines (ATCC) B. Image of cells incubated after chemical treated




## RESULTS

The chemical solvent DMSO was used as the negative control group. The toxicity of the solvent was compared with that of physiological saline (SF) in the study. ED<sub>50</sub> of thymoquinone as 100 µM and the ED<sub>50</sub> of cisplatin were determined as 200 µM in the preliminary study. Chemical treatments were administered on all cell lines at doses of 10, 100, 200 µM. Cell death by SF administration wasn't detected in any of the cell lines. The toxicity of DMSO wasn't observed on any tumoral or nontumoral cell lines. Cell lines of non-cancerous pleural epithelium lysis in RPMI due to temperature changes during incubation and could not be used. Therefore, BEAS2B (the bronchial epithelium) was used as the nontumoral cells.


The effect of thymoquinone at 10 µM doses on malignant pleural mesothelioma (CRL-5820) was statistically significant ( $p < 0.003$ ). However, there was no significant effect of cisplatin when compared with DMSO at this dose. 100 µM thymoquinone ( $p < 0.001$ ) was more effective on malignant mesothelioma cell lines than both the same and 200 µM doses cisplatin. At 200 µM doses, both chemicals were effective ( $p < 0.001$ ). Thymoquinone was more effective than cisplatin at 200 µM doses ( $p < 0.001$ ). However, these doses were lethal effect for thymoquinone and effective dose for cisplatin (Figure 2).

**Figure 2. Viability of cells after chemical exposure in pleural malignant mesothelioma**




There was no statistically significant effect of either chemical at 10 µM doses in small cell lung cancer cell lines (CRL-5853). Thymoquinone 100 µM doses were more effective than both 100 µM<sup>(p<0.001)</sup> and 200 µM<sup>(p<0.03)</sup> doses of cisplatin. The effects of 100 µM<sup>(p<0.05)</sup> and 200 µM<sup>(p<0.004)</sup> cisplatin were statistically significant compared to DMSO. However, the effect of 100 µM cisplatin on cell viability wasn't at least 50%. Thymoquinone was more effective than cisplatin at 200 µM doses<sup>(p<0.001)</sup>. However, these doses were lethal effect for thymoquinone and effective dose for cisplatin (Figure 3).

**Figure 3. Viability of cells after chemical exposure in small cell lung cancer**



There was no statistically significant effect of either chemical at 10 µM doses in non-cancerous bronchial epithelium cell lines (BEAS2B). Thymoquinone 100 µM doses were more effective than 100 µM<sup>(p<0.001)</sup> doses of cisplatin and, thymoquinone 200 µM doses were more effective than cisplatin at 200 µM doses<sup>(p<0.001)</sup>. There was no statistically significant difference between the effects of both chemicals at effective doses. Therefore, toxicities were similar at effective doses (Figure 4).

**Figure 4. Viability of cells after chemical exposure in non-tumoral bronchial epithelium**




## DISCUSSION

The lung cancer is the cause of 25% of cancer deaths in both men and women. It is examined in two categories as small cell (SCLC) and non-small cell lung cancer (NSCLC). SCLC comprises about 15% of lung cancers, while NSCLC comprises for 85% [7]. Treatments include surgery, chemotherapy, radiotherapy and immunotherapy. Small cell lung cancer is a progressive disease that can usually be detected at an advanced stage at diagnosis. Therefore, chemotherapy is very important in the treatment of this disease. Despite its cellular toxicity, cisplatin, an alkylating agent, is frequently used [8]. This chemotherapeutic agent is preferred among many combination treatments. Recently, immunotherapy and targeted agents have greatly improved survival in the treatment of NSCLC. Unfortunately, it isn't very successful in SCLC [9]. Platinum is among the chemical agents frequently used in the chemotherapy protocol. Because of, cisplatin was used on the SCLC in the study.

Thymoquinone with a molecular weight of 164.2 g/mol is achieved from the plant *Nigella Sativa*. Studies on the anticancer and antitumoral effects of this bioactive substance reported in the literature. It was proven that thymoquinone significantly inhibited the foci of lung metastases in a the study [15]. It was used to compare thymoquinone with cisplatin because of its antitumoral anticancer activities in our study. Chemicals treated to cell lines had to be dissolved in a solvent. For this purpose, dimethyl sulfoxide solution (DMEM) was used. Both chemicals were dissolved in DMEM. Since each chemical may have toxicity on living cells, a saline (SF) negative control group was made for comparison with DMEM. There was no statistically significant difference between DMEM and saline in all of the mesothelioma, small cell lung cancer and noncancerous bronchial epithelial cell lines. Therefore, it was accepted that the chemical solvent wasn't toxic to living cells. Doses that reduced the viability of cancer cell lines by at least 50% were calculated. This value was specified as the traditional ED50 dose in the study. The ED50 of thymoquinone was 100  $\mu$ M and that of cisplatin was 200  $\mu$ M. The effects of both chemicals at ED50 doses were statistically significant when compared with DMSO. At 200  $\mu$ M doses, thymoquinone was more effective than the cisplatin, but this was unacceptable. Because 200  $\mu$ M, the ED50 dose for cisplatin, was the lethal dose for thymoquinone. Therefore, the comparison was made at the ED50 doses of the chemicals. Accordingly, 100  $\mu$ M dose of thymoquinone was more effective than 200  $\mu$ M dose of cisplatin. No statistically significant difference was found in the comparison of the ED50 of both chemicals on noncancerous bronchial epithelium. Their effects on the bronchial epithelium were found to be similar. As a result, thymoquinone was shown to be more effective than cisplatin in small cell lung cancer cell lines (Figure 3,5).

**Figure 5. Effects of thymoquinone and cisplatin at effective doses on all cancer cell lines**



Malignant mesothelioma is a fatal disease that usually originates from the pleura, rarely from the peritoneum. The main risk factor in malignant mesothelioma is asbestos exposure. Pleural mesothelioma composes for 90% of all mesotheliomas. It has a poor prognosis and a very low 1-year median survival despite chemotherapy [10]. Extrapleural pneumonectomy (EPP) is among the surgical approaches in the treatment of pleural mesothelioma. This method involves resection a lung, parietal

pleura, pericardium, and sections of diaphragm. However, a major surgical treatment and it isn't suitable for every patient. Lung parenchyma-sparing surgical approaches have been recommended in recent years [11]. Therefore, pleurectomy decortication are done a common surgical treatment in Malignant pleural mesothelioma (MPM). Hyperthermic intrathoracic chemoperfusion (HITOC) with cisplatin at 42 °C can be performed in the same surgery after completion of pleurectomy decortication [12]. A greater depth of penetration of the chemotherapeutic agent cisplatin administered with HITOC is achieved and induction of signaling pathways for tumor cell apoptosis is activated [13-15]. Because of, cisplatin was used on the MPM in the study.

The effects of both chemicals at ED50 doses were statistically significant when compared with DMSO in MPM. At 200 µM doses, thymoquinone was more effective than the cisplatin, but this value the lethal dose for thymoquinone. Therefore, 100 µM dose of thymoquinone was more effective than 200 µM dose of cisplatin. No statistically significant difference was found in the comparison of both chemicals on noncancerous bronchial epithelium and those were found to be similar. Thymoquinone was shown to be more effective than cisplatin in small cell lung cancer cell lines in malignant pleural mesothelioma (Figure 2,5). The effects of chemicals on cancer cell lines were compared with each other. Although the effect of thymoquinone at a dose of 100 µM was greater in small cell lung cancer cell lines, there was no statistical difference. Thymoquinone was similarly effective in both SCLC and MPM cell lines. Cisplatin was more effective on SCLC cell lines at a dose of 200 µM and it was statistically significant. As a result, cisplatin was more effective than MPM in SCLC cell lines.

## CONCLUSIONS

Thymoquinone at a dose of 100 µM was more effective than cisplatin at a dose of 200 µM on both small cell lung cancer and malignant pleural mesothelioma cell lines. Cisplatin was more effective in small cell lung cancer than malignant pleural mesothelioma at a dose of 200 µM. The effects of thymoquinone were similar in both cancer cell lines.

## ETHICAL APPROVAL

The study was carried out on cancer cell lines in the cell culture laboratory and accordance with international standards.

## REFERENCES

- 1.Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. *Mod Pathol* 2012;25: 512-30.
- 2.Yaman M. İ.Ü.Cerrahpaşa Tıp Fakültesi Sempozyum Dizisi No:58 2007;157-168
- 3.Sakin A, Aldemir MN, Alay M. The Effect of Choice of Platinum On Survival and Factors Affecting Survival In Metastatic Small Cell Lung Cancer: A Single Center Experience. *Van Tıp Derg* 2021;28(1):84-90
- 4.Zha L, Kitamura Y, Kitamura T, Liu R, et al. Population-based cohort study on health effects of asbestos exposure in Japan. *Cancer Sci.* 2019 Mar;110(3):1076-1084.
- 5.Sumeet V.J, Jason M.W. Malignant Mesothelioma. Treasure Island (FL):StatPearls Publishing; 2022 Jan Last Update:July 4, 2022.
- 6.Roepke M, Diestel A, Bajbouj K, Walluscheck D, et al. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. *Cancer Biol Ther* 2007; 6(2):160-9.
- 7.Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. *Mod Pathol.* 2012 Jan;25 Suppl 1:S18-30.
- 8.J-L Pujol, Carestia&J-P Daurés. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. *British Journal of Cancer* 2000;83:8-15.
9. Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. *N Engl J Med.* 2020;383(7):640-649.
- 10.Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. *Lancet* 2021;397:375–86.
- 11.Popat S, Baas P, Faivre-Finn C, Girard N, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† *Ann. Oncol.* 2021;33:129–142.

12. Klotz LV, Lindner M, Eichhorn ME, Grutzner U, et al. Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma. *J Thorac Dis.* 2019;11:1963–1972.
13. Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. *J Thorac Cardiovasc Surg* 2013;145:955–963.
14. Rajiv S, Laura VK, Julia G. Current Management and Future Perspective in Pleural Mesothelioma. *Cancers (Basel).* 2022;14(4):1044.
15. Ammad AF, Rukset A, Baojun X. Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone. *Int J Mol Sci* 2022;23(11):6311.

UNDER PEER REVIEW